Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Anika Therapeutics Q2 Adj EPS $0.06 Beats $(0.27) Estimate, Sales $44.30M Beat $40.56M Estimate

Author: Benzinga Newsdesk | August 08, 2023 04:43pm
Anika Therapeutics (NASDAQ:ANIK) reported quarterly earnings of $0.06 per share which beat the analyst consensus estimate of $(0.27) by 122.22 percent. This is a 150 percent increase over losses of $(0.12) per share from the same period last year. The company reported quarterly sales of $44.30 million which beat the analyst consensus estimate of $40.56 million by 9.23 percent. This is a 11.71 percent increase over sales of $39.66 million the same period last year.

Posted In: ANIK


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist